In-Situ Vaccine Producion
In-Situ, Virus-Like Particle (VLP) Delivery
Esperovax has developed a proprietary method for bioengineering probiotic yeast to deliver continuous and high concentrations of vaccine antigen in the gut. These antigens are delivered in the form of enveloped virus like particles (eVLPs) right to the lymphoid tissue (payers patches) of the gut mucosa, inducing strong immune protection.
EVLP, RVLP, or self-amplifying AVLPs
Our oral delivery platform uses two different methods to deliver antigens, either through proteins produced as part of the VLP (a standard EVLP), or capturing mRNA inside the particle. The RNA can be mRNA (RVLP), or a self-amplifying RNA (AVLP).